The Fat Loss Stack
Accelerated Fat Loss
Weight Loss & Fat Burning
Description
A multi-pathway approach to fat loss combining GLP-1 receptor agonism for appetite suppression, a GH fragment targeting lipolysis, and a metabolic activator that increases energy expenditure.
🔬 How It Works
Semaglutide reduces appetite and slows gastric emptying through GLP-1 receptor activation. AOD-9604 is the fat-burning fragment of growth hormone that stimulates lipolysis without the growth-promoting effects. 5-Amino-1MQ inhibits NNMT enzyme, boosting NAD+ and cellular metabolism. Together, they attack fat from three angles: reduced intake, increased fat breakdown, and elevated energy expenditure.
⚡ Synergy Explanation
Semaglutide powerfully reduces caloric intake through appetite suppression. AOD-9604 directly stimulates fat cell lipolysis, making stored fat more available as fuel. 5-Amino-1MQ increases cellular energy expenditure by boosting NAD+ levels. The triple mechanism creates a caloric deficit from both the intake and expenditure sides while specifically targeting fat stores.
🧬 Peptides in This Stack
Semaglutide
SubcutaneousGLP-1 agonist — suppresses appetite, slows gastric emptying
AOD 9604
SubcutaneousGH fragment — targets lipolysis without growth effects
5-Amino-1MQ
OralNNMT inhibitor — boosts metabolism and NAD+ levels
⏰ Timing & Administration
Duration: 12-16 weeks
Time of Day: Semaglutide weekly; AOD-9604 morning fasted; 5-Amino-1MQ with meals
Notes: Dose titrate semaglutide slowly over 4 weeks. Stay well hydrated. Maintain adequate protein intake to preserve muscle.
✅ Expected Results
- •Significant appetite reduction within 1-2 weeks
- •5-15% body weight loss over 12-16 weeks
- •Reduced visceral fat
- •Improved metabolic markers (blood sugar, insulin)
- •Increased energy expenditure
⚠️ Warnings & Precautions
- ⚠Nausea is common when starting semaglutide — titrate slowly
- ⚠May cause gastrointestinal side effects
- ⚠Monitor for signs of pancreatitis
- ⚠Maintain adequate protein intake to minimize muscle loss
- ⚠Not recommended for those with history of medullary thyroid cancer